Last updated: March 25, 2026
Semaglutide 2.4mg (Wegovy) produced average weight loss of 14.9% (≈34 lbs) over 68 weeks in the STEP 1 Phase 3 trial — roughly double the weight loss of older obesity medications. About 1 in 3 participants lost more than 20% of body weight.
A visual breakdown of the landmark STEP 1 trial for Wegovy/Ozempic — the most widely prescribed GLP-1 weight loss medication
Mechanism of Action
Semaglutide is a selective GLP-1 receptor agonist that mimics the natural GLP-1 hormone. It acts on multiple pathways simultaneously to reduce body weight.
Acts on hypothalamic GLP-1 receptors to reduce hunger signals and increase satiety, leading to naturally reduced caloric intake without constant willpower.
Slows the rate at which food leaves the stomach, prolonging feelings of fullness after meals and reducing overall food consumption throughout the day.
Enhances glucose-dependent insulin secretion from pancreatic beta cells, improving blood sugar control — the original mechanism that led to FDA approval for type 2 diabetes.
Suppresses inappropriate glucagon release, reducing hepatic glucose output and contributing to improved metabolic control alongside weight reduction.
STEP 1 Trial Data
Average percent body weight change at 68 weeks. Semaglutide 2.4mg weekly vs placebo, both with lifestyle intervention.
Difference: −12.4 percentage points (p<0.001). Participants on semaglutide lost over 6× more weight than those on placebo, both groups receiving lifestyle counseling.
68-Week Outcomes
Percentage of participants achieving clinically meaningful weight loss thresholds. Semaglutide vs placebo at 68 weeks.
Broader Evidence
STEP 1 was part of a comprehensive clinical program. Here's how semaglutide performed across different populations and study designs.
Competitive Landscape
Semaglutide vs the next-generation weight loss medications. Cross-trial comparisons — see caveat below.
Safety Profile
Reported adverse events from the STEP 1 trial. Semaglutide 2.4mg vs placebo. Most are GI-related and dose-dependent.
Only 4.5% of semaglutide participants discontinued due to GI adverse events, compared to 0.8% in the placebo group. The vast majority of side effects were mild to moderate and resolved over time.
Semaglutide uses a gradual dose escalation over 16–20 weeks, starting at 0.25mg and increasing monthly. This slow titration significantly reduces GI side effects compared to starting at the full dose.
GI side effects are a known class effect of all GLP-1 receptor agonists. They are largely a consequence of the drug's mechanism — slowed gastric emptying and appetite suppression naturally affect the digestive system.
Dosing Protocol
Semaglutide uses a gradual dose escalation designed to minimize GI side effects while building toward the maximum therapeutic dose. The standard Wegovy protocol runs over 17+ weeks before reaching maintenance.
Study Metadata
All primary data on this page is sourced from the STEP 1 NEJM publication. Full citation below.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Self-Assessment
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Bottom Line
Separating established findings from open questions about semaglutide for weight management.
Continue Reading
Calculators, vendor guides, and dosing information for weight loss peptides.
Based on published STEP 1 clinical trial data (NEJM 2021, n=1,961) at the 2.4 mg/week maintenance dose. Individual results vary.
Semaglutide begins binding GLP-1 receptors in the hypothalamus and brainstem, producing reduced appetite and earlier feelings of fullness. Most participants report noticeable hunger reduction within the first week. Nausea is the most common side effect (affecting ~44% of participants at some point in STEP 1) and is most pronounced during dose escalation at this stage.
STEP 1 data shows approximately 2–5% average body weight reduction by week 4. Cravings for high-fat and high-sugar foods reduce significantly — an effect driven by GLP-1 receptor activity in brain reward circuits (mesolimbic pathway). Dose typically escalates to 0.5 mg/week. GI side effects remain the primary complaint but are manageable for most.
By week 12, STEP 1 participants had lost an average of 6.1% of body weight (on the path toward the 68-week average of 14.9%). Fasting blood glucose, triglycerides, and systolic blood pressure all begin improving. Participants are typically approaching or at maintenance dosing (1.7–2.4 mg/week). Most GI side effects have resolved as the body adapts.
The full STEP 1 trial (68 weeks) showed an average weight loss of 14.9% — with more than one-third of participants losing ≥20% of body weight. HbA1c improves by approximately 0.5–1.0 percentage points in those with insulin resistance or prediabetes. The subsequent SELECT cardiovascular outcomes trial (N Engl J Med 2023, PMID 37633483) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in overweight/obese adults with established cardiovascular disease.
Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Semaglutide (Wegovy/Ozempic) is an FDA-approved prescription medication — it should only be used under the supervision of a qualified healthcare provider. Always consult with your doctor before starting any medication or treatment protocol. Data sourced from published peer-reviewed research (NEJM 2021, PMID: 33567185).
⚕️ Semaglutide is a prescription medication. Always consult a healthcare provider before starting treatment.
In the STEP 1 Phase 3 trial, participants on semaglutide 2.4mg (Wegovy) lost an average of 14.9% of their body weight over 68 weeks — approximately 34 lbs on average. About 1 in 3 participants lost more than 20% of body weight. Results vary based on dose, diet adherence, and individual metabolic response.
Semaglutide typically produces noticeable appetite reduction within the first 1–4 weeks. Meaningful weight loss (≥5%) is usually observed by week 12–16. Peak weight loss is generally achieved after 52–68 weeks of continuous treatment at the full therapeutic dose. Dose is gradually escalated over the first several months to minimize side effects.
The most common semaglutide side effects are nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%), particularly during dose escalation. Most gastrointestinal side effects are mild-to-moderate and improve after the first 4–8 weeks. Rare but serious risks include pancreatitis, gallbladder disease, and a theoretical thyroid cancer risk based on animal studies.
Semaglutide has been used in type 2 diabetes treatment (Ozempic) since 2017, providing several years of real-world safety data. The SUSTAIN and STEP trial programs showed a favorable safety profile over 1–2 years. The main concerns are GI side effects (which typically improve), and the need for continued use to maintain weight loss — most people regain weight within a year of stopping treatment.